Engineered Tissue Solutions and Transdiagen Partner to Pioneer Gene Expression Research in Chronic Wound Healing
ROLLA, MO & CARDIFF, UK, August 7, 2025 — Engineered Tissue Solutions (ETS), a Missouri-based medical device innovator, today announced a groundbreaking collaboration with UK-based precision medicine company Transdiagen to assess gene expression changes in chronic wounds treated with Mirragen®, ETS’s unique borate-based bioactive glass fiber matrix. This marks the first time any skin substitute (also referred to as a CTP or CAMP) has undergone such a genomic-level evaluation in a chronic wound environment.
Through this collaboration, Transdiagen will analyze molecular changes in chronic wound tissue through its proprietary and clinically validated gene expression signatures pre- and post-treatment with Mirragen. ETS has contracted Transdiagen to lead this effort as part of a broader scientific initiative to better understand how Mirragen modulates the wound microenvironment and supports tissue regeneration at the genetic level.
AJ Ford, CEO of ETS, commented:
“This is a first-of-its-kind study in wound care. By evaluating gene expression in real-world chronic wounds treated with Mirragen, we’re advancing the scientific rigor behind skin substitutes/CTPs/CAMPs and reinforcing our commitment to evidence-driven innovation.”
James Harding, CEO of Transdiagen, added:
“We are thrilled to work with ETS on this pivotal study. This collaboration represents a meaningful step toward unlocking a deeper understanding of how bioactive glass promotes healing across a range of wound etiologies…an understanding that will help set a new scientific standard for chronic wound therapies.”
The study is slated to begin in Q3 2025, with initial data expected to provide novel insights into biological mechanisms of wound healing and product performance. The findings may also inform future development of precision-guided wound care strategies.
For media inquiries, please contact:
Engineered Tissue Solutions
Media Relations
ets.support@heraeus.com
573-202-2550
Transdiagen
Communications Team
Email: info@transdiagen.com
Phone: +44 29 5555 1234
About Engineered Tissue Solutions
Engineered Tissue Solutions (ETS) is a medical device company dedicated to empowering wound healing with its innovative borate-based bioactive glass technology. Its flagship commercial offerings, Mirragen and MirraSurg, are used in chronic wound care and surgical wound care in a variety of healthcare settings across the US. As a member of the Heraeus Group, a globally diversified family-owned technology company, ETS draws upon a legacy of excellence and materials engineering innovation. Learn more about ETS at www.EngineeredTissue.com or the Heraeus Group at www.Heraeus.com.
Mirragen Advanced Wound Matrix and MirraSurg Wound Matrix are intended for use in the management of wounds under the supervision of a healthcare professional. Consult the IFU for a complete list of indications and safety information
About Transdiagen
Transdiagen (TDG) is a precision medicine company developing drugs and diagnostics for chronic wound healing and tissue regeneration. TDG is driven by the molecular understanding and clinical outcome of chronic wounds and to delivering the right treatment, to the right patient, at the right time.
TDG has developed novel Ex Vivo models built on clinically validated mRNA biomarkers linking clinical data and patient outcomes. This is the most advanced disease understanding platform for chronic wounds, and powers the creation of novel diagnostics and drugs. The TDG development models and molecular insights translate laboratory data to clinical outcomes, transforming the development lifecycle of novel interventions directing efficacy, product development, disease, and patient selection. TDG is headquartered in the UK.